Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Биотехнологии

Mr. Will  Tilton

Senior Vice President, Head of Strategy & Chief of Staff

Ms. Alison  Nasisi

Executive Vice President & Chief People Officer

Mr. Ryan E. Brown J.D.

Executive Vice President, General Counsel & Corporate Secretary

Dr. Diane L. Berry Ph.D.

Executive Vice President and Chief of Global Policy & Advocacy Officer

Dr. Louise R. Rodino-Klapac Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Research & Development

Mr. Dallan  Murray

Executive Vice President & Chief Customer Officer

Ms. Francesca T. Nolan

Executive Director of Investor Relations and Corporate Communications

Mr. Douglas S. Ingram Esq.

President, Chief Executive Officer & Director

Mr. Ian Michael Estepan

Executive Vice President & Chief Financial Officer

Mr. Bilal  Arif

Executive Vice President & Chief Technical Operations Officer

Име	Пазарна капитализация
Comera Life Sciences Holdings, Inc.	0M
CytoTools AG	0M
Purple Biotech Ltd.	0M
Starpharma Holdings Limited	0M
Arcutis Biotherapeutics, Inc.	0M
Aditxt, Inc.	0M

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. Списък на конкурентите

Основни конкуренти